Equitable Holdings
EQH
$41.19
+1.45%
Equitable Holdings, Inc. is a diversified financial services company operating primarily in the insurance and asset management sectors, providing retirement, asset management, and wealth management solutions to individual and institutional clients. The company is a well-established player with a significant presence in the annuity and retirement savings market, deriving the majority of its revenue from its Retirement segment. The current investor narrative is heavily influenced by the company's volatile quarterly earnings performance, including a significant net loss in Q3 2025 followed by a return to profitability in Q4, which has created uncertainty around its core earnings power. Recent news of substantial share repurchases signals management's confidence in the stock's value, but this is juxtaposed against a backdrop of declining revenue and questions about the sustainability of its profitability.…
EQH
Equitable Holdings
$41.19
Related headlines
Investment Opinion: Should I buy EQH Today?
Rating & Thesis: Hold. EQH is a high-risk, high-potential-reward turnaround story where extreme valuation de-rating clashes with demonstrably unstable fundamentals; the stock is only suitable for speculative, risk-tolerant investors who can stomach volatility while awaiting evidence of sustained earnings recovery. This neutral stance is anchored by the limited but bullish analyst sentiment, yet tempered by the lack of a concrete fundamental catalyst for a sustained reversal.
Supporting Evidence: The primary valuation metric, the trailing PS ratio of 1.22x, sits at a deep 71% discount to the stock's own historical average, suggesting significant pessimism is priced in. However, this is justified by a 9.5% YoY revenue decline and a TTM net margin of -11.83%. The forward PE of 4.80x, based on an estimated EPS of $12.40, implies the market expects a dramatic profit recovery, but this expectation is highly speculative given recent earnings volatility. Positive supporting factors include strong TTM free cash flow of $737 million funding shareholder returns and a recent 12.09% monthly price bounce indicating potential bottoming.
Risks & Conditions: The two biggest risks that could invalidate a potential buy thesis are 1) another large quarterly net loss, confirming earnings instability, and 2) further revenue contraction. This Hold rating would upgrade to a Buy if the company reports two consecutive quarters of stable, positive net income with revenue stabilization, confirming the Q3 loss was an anomaly. It would downgrade to a Sell on a breakdown below the $35.20 support level coupled with deteriorating cash flow. Based on the current data, the stock appears fairly valued relative to its troubled fundamentals but deeply undervalued relative to its historical norm and potential normalized earnings power, creating a high-risk asymmetry.
Sign up to view all
EQH 12-Month Price Forecast
EQH presents a binary outcome heavily dependent on the normalization of its earnings. The current neutral stance reflects the high uncertainty: the valuation is compelling, but the fundamentals are demonstrably broken. The forward PE of 4.80x suggests the market is betting on a recovery, making the next 1-2 quarterly earnings reports critical inflection points. The stance would upgrade to bullish on evidence of sustained profitability (two clean quarters) and downgrade to bearish on a confirmation of recurring large losses or a breakdown of the $35 technical support. For now, it is a 'show me' story where the risk/reward is balanced but skewed towards high volatility.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Equitable Holdings's 12-month outlook, with a consensus price target around $53.55 and implied upside of +30.0% versus the current price.
Average Target
$53.55
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$33 - $54
Analyst target range
Analyst coverage for EQH is extremely limited, with only two analysts providing estimates, indicating insufficient coverage for a robust consensus view. This limited coverage is typical for a mid-cap financial stock and can lead to higher volatility and less efficient price discovery, as institutional interest and research scrutiny are lower. The available data shows estimated EPS for the next period averaging $12.40, with a range from $10.97 to $13.36, but without a consensus price target or recommendation distribution, the overall analyst sentiment cannot be quantitatively assessed. The institutional ratings data provides a clearer signal, showing a pattern of reiterated bullish stances from major firms. Recent actions from Morgan Stanley, Wells Fargo, UBS, JP Morgan, and Barclays in early 2026 have all been 'Overweight' or 'Buy' ratings, with JP Morgan upgrading from 'Neutral' to 'Overweight' in January. This consistent bullishness from the limited set of covering analysts, despite the stock's poor performance, suggests a belief that the current price dislocation presents a buying opportunity, likely predicated on expectations of earnings normalization and the supportive impact of share repurchases.
Bulls vs Bears: EQH Investment Factors
The investment debate for EQH centers on a classic value trap versus deep value recovery scenario. The bear side currently presents stronger evidence, anchored in the company's demonstrable fundamental deterioration—declining revenue, erratic profitability, and severe underperformance. However, the bull case is supported by an extreme valuation de-rating, strong free cash flow, and analyst conviction that a return to normalized earnings is imminent. The single most important tension is whether the company's volatile quarterly results, particularly the massive Q3 2025 loss, represent a one-time anomaly or a symptom of a broken business model. The resolution of this question—through sustained demonstration of stable, positive earnings—will determine if the stock is a compelling value play or a value trap.
Bullish
- Extreme Valuation De-rating: The stock trades at a trailing PS ratio of 1.22x, a 71% discount to its historical PS of 4.15x from Q4 2025. This severe de-rating, coupled with the stock trading just 25% above its 52-week low, suggests significant pessimism is priced in, offering a potential value opportunity if fundamentals stabilize.
- The company generated $737 million in TTM free cash flow, providing ample resources for shareholder returns. Recent news of substantial share repurchases signals management's confidence and provides a tangible EPS tailwind, directly supported by the company's robust liquidity position with a current ratio of 25.5.
- Analyst Conviction Amid Weakness: Despite the stock's 14.4% annual decline, major institutions like JP Morgan, Morgan Stanley, and Barclays have reiterated or upgraded to 'Overweight'/'Buy' ratings in early 2026. This consistent bullish stance from covering analysts suggests a belief that the current price dislocation presents a buying opportunity based on expected earnings normalization.
- Forward PE Implies Profit Recovery: The forward PE ratio of 4.80x, based on an estimated EPS of $12.40, is extremely low and indicates the market anticipates a sharp return to profitability from the current negative trailing earnings. This forward multiple, if realized, would represent a significant valuation re-rating catalyst.
Bearish
- Erratic & Declining Profitability: The company's earnings are highly volatile, swinging from a $1.31 billion net loss in Q3 2025 to a $215 million profit in Q4. The TTM net margin is -11.83% and ROA is -0.20%, indicating a fundamental lack of consistent earnings power and inefficient use of assets.
- Revenue Contraction & Instability: Q4 2025 revenue of $3.28 billion declined 9.5% year-over-year. The multi-quarter trend shows extreme volatility, from $3.90B in Q1 down to $1.45B in Q3, indicating an unstable top line that complicates the growth narrative and investment case.
- Severe Underperformance & Downtrend: The stock has declined 14.39% over the past year, underperforming the S&P 500 by over 43 percentage points. It remains in a pronounced downtrend, trading 25% below its 52-week high, with a max drawdown of -37.01%, reflecting persistent negative momentum and technical damage.
- Negative Shareholder Equity: The balance sheet shows a debt-to-equity ratio of -88.68, indicating negative shareholder equity. This complicates traditional leverage assessment and valuation, and signals potential financial stress or accounting complexities that could deter value-focused investors.
EQH Technical Analysis
The stock is in a pronounced downtrend, having declined 14.39% over the past year, starkly underperforming the S&P 500's 29.04% gain. With a current price of $42.17, it is trading near the lower end of its 52-week range, approximately 25% above its 52-week low of $35.20 but 25% below its 52-week high of $56.61, positioning it as a potential value opportunity but also indicating significant bearish momentum and technical damage. Recent momentum shows a short-term bounce, with the stock up 12.09% over the past month, which diverges positively from the longer-term downtrend; however, this recovery follows a sharp 9.12% decline over the prior three months, suggesting the recent strength may be a corrective rally within a broader bearish structure rather than a confirmed reversal. Key technical support is clearly defined at the 52-week low of $35.20, while resistance lies at the recent recovery highs near $49.25 from early January 2026. A decisive break above the $49-$50 zone would be necessary to signal a potential trend reversal, while a breakdown below $35 would likely trigger a new leg lower. The stock's beta of 1.11 indicates it is moderately more volatile than the broader market, which is typical for financial stocks, but its relative strength readings of -43.43 over one year highlight severe and persistent underperformance that requires a fundamental catalyst to reverse.
Beta
1.13
1.13x market volatility
Max Drawdown
-37.0%
Largest decline past year
52-Week Range
$35-$57
Price range past year
Annual Return
-24.1%
Cumulative gain past year
| Period | EQH Return | S&P 500 |
|---|---|---|
| 1m | +7.8% | +8.2% |
| 3m | -5.5% | +9.0% |
| 6m | -7.9% | +10.5% |
| 1y | -24.1% | +26.5% |
| ytd | -14.1% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EQH Fundamental Analysis
Revenue growth is inconsistent and recently negative, with Q4 2025 revenue of $3.28 billion representing a 9.5% year-over-year decline from the prior-year quarter. The multi-quarter trend is highly volatile, with revenue swinging from $3.90 billion in Q1 2025 down to $1.45 billion in Q3 2025 before the Q4 rebound, indicating significant instability in the top line that complicates the growth narrative and investment case. The Retirement segment is noted as the primary revenue driver, but without detailed segment growth data, the sustainability of this engine is unclear amid the overall revenue contraction. Profitability is highly erratic, with the company swinging from a net income of $215 million in Q4 2025 to a massive net loss of $1.31 billion in Q3 2025. The gross margin of 88.07% in Q4 is robust, but this is overshadowed by a trailing twelve-month net margin of -11.83%, indicating that while the core insurance underwriting may be profitable, significant losses are occurring elsewhere on the income statement, likely from investment-related activities. The path to consistent profitability is uncertain, as evidenced by the wild quarterly swings in net income and operating income. The balance sheet shows a strong liquidity position with a current ratio of 25.50, but this is offset by a highly unusual and negative debt-to-equity ratio of -88.68, which typically indicates negative shareholder equity and complicates traditional leverage assessment. Free cash flow over the trailing twelve months is a healthy $737 million, providing the company with internal resources to fund shareholder returns, as evidenced by its active share repurchase program. However, the negative ROA of -0.20% suggests the company is not efficiently generating profits from its asset base, raising questions about capital allocation.
Quarterly Revenue
$3.3B
2025-12
Revenue YoY Growth
-0.09%
YoY Comparison
Gross Margin
+0.88%
Latest Quarter
Free Cash Flow
$737000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EQH Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as earnings-based multiples are not meaningful. The stock trades at a trailing PS ratio of 1.22x, which is a straightforward measure of its market value relative to revenue generation in the absence of stable profits. A forward PE ratio of 4.80x is also available, suggesting the market anticipates a return to significant profitability, but the wide gap between this and the negative trailing PE underscores the extreme volatility and uncertainty in earnings. Peer comparison data for the Insurance - Diversified industry is not available in the provided dataset, preventing a direct sector premium/discount analysis. In the absence of industry averages, the PS ratio of 1.22x must be assessed in the context of the company's own fundamentals—namely, declining revenue and erratic profitability—which likely justify a discounted multiple compared to more stable financial services peers, though this cannot be quantified. Historically, the stock's own valuation presents a mixed picture. Its current PS ratio of 1.22x is significantly below its historical PS of 4.15x from Q4 2025, indicating a substantial de-rating. This de-rating aligns with the stock's price decline and deteriorating fundamentals over recent quarters. Trading near the bottom of its own historical valuation band suggests the market has priced in significant pessimism, potentially offering a value opportunity if the company can stabilize its operations, but it also reflects genuine fundamental deterioration that may not be temporary.
PE
-10.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~64x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the extreme volatility and inconsistency of core earnings, as evidenced by the swing from a $1.31 billion net loss to a $215 million profit in consecutive quarters. This erratic profitability, combined with a TTM net margin of -11.83%, makes forecasting and valuation exceptionally difficult. Furthermore, the company's revenue is contracting, with Q4 2025 showing a 9.5% YoY decline, raising questions about the sustainability of its primary Retirement segment. While free cash flow of $737 million is strong, the negative ROA of -0.20% indicates poor capital efficiency.
Market & Competitive Risks: The stock carries significant valuation compression risk, as its current PS ratio of 1.22x represents a 71% discount to its own recent history, suggesting the market has already severely de-rated it. Its beta of 1.11 indicates moderate sensitivity to broader market moves, but its severe relative underperformance (-43.43 vs. SPY over one year) highlights company-specific issues outweighing macro factors. The limited analyst coverage (only 2 analysts) increases the risk of sharp price moves on news, as institutional scrutiny is low. As a financial services firm, it also faces inherent risks from interest rate fluctuations and credit market conditions.
Worst-Case Scenario: The worst-case scenario involves a failure to stabilize earnings, with another large quarterly loss confirming the Q3 2025 result was not an anomaly. This would trigger a loss of analyst confidence, a halt to the share repurchase program, and a further de-rating of the already depressed valuation. A breakdown below the key technical support at the 52-week low of $35.20 could initiate a new leg down. In this adverse scenario, a realistic downside from the current price of $42.17 is approximately -17% to the 52-week low, with potential for further declines if negative momentum accelerates, mirroring the stock's maximum historical drawdown of -37%.
FAQ
The key risks are, in order of severity: 1) Earnings Instability Risk: The company has shown an inability to generate consistent profits, with a $1.31 billion net loss in Q3 2025. 2) Revenue Contraction Risk: Q4 2025 revenue declined 9.5% YoY, questioning the growth trajectory of its core Retirement segment. 3) Financial Statement Risk: The negative debt-to-equity ratio of -88.68 indicates negative shareholder equity, complicating analysis and signaling potential financial stress. 4) Liquidity & Sentiment Risk: With only two covering analysts, the stock is vulnerable to sharp moves on limited news flow and could face selling pressure if institutional interest wanes.
The 12-month forecast for EQH is highly bifurcated, with a base case target range of $42-$50 (50% probability), a bull case of $56-$65 (25% probability), and a bear case of $30-$35 (25% probability). The base case, which is most likely, assumes the company avoids another major loss, earnings remain volatile but positive near the $12.40 EPS estimate, and the stock trades in a range. The key assumption behind this forecast is that the catastrophic Q3 2025 loss proves to be an isolated event rather than a recurring pattern. The wide range of outcomes underscores the stock's high uncertainty.
EQH is both deeply undervalued relative to its history and arguably fairly valued relative to its current troubled fundamentals. Its trailing Price-to-Sales (PS) ratio of 1.22x is 71% below its historical PS of 4.15x, indicating extreme de-rating. However, this discount is justified by a 9.5% revenue decline and a negative TTM net margin of -11.83%. The forward PE of 4.80x suggests the market is pricing in a sharp earnings recovery. Therefore, the stock is undervalued if a return to normalized profitability occurs, but it is not necessarily cheap given the present operational instability.
EQH is a high-risk, speculative buy only suitable for investors with a strong tolerance for volatility. The potential reward is significant, with a forward PE of just 4.80x implying massive upside if earnings normalize, and the stock trades at a 71% discount to its own historical PS ratio. However, the key risk is the company's erratic profitability, evidenced by a $1.5 billion swing between Q3 and Q4 2025 results. It could be a good buy for a speculative portion of a portfolio if you believe management can stabilize operations, but it is not a good buy for conservative investors seeking stability or reliable income.
EQH is not suitable for short-term trading due to its high volatility (beta of 1.11) and unpredictable quarterly earnings, which can cause sharp, news-driven price swings. It is more appropriate for a medium- to long-term investment horizon of 2-3 years, allowing time for the company's turnaround narrative to either prove itself or fail. The investment thesis is based on earnings normalization and valuation repair, processes that require multiple quarters to confirm. Given the lack of a meaningful dividend (yield of 2.64%), it is not an income stock, and investors must be prepared to hold through significant volatility while awaiting fundamental improvement.